ABRAXAS2 and hepatocellular carcinoma: To further investigate whether downregulation of ABRO1 is correlated with survival in HCC patients, two independent cohorts of HCC patients, Cohort 1 (90 patients) and Cohort 2 (161 patients), were analysed.